Sarepta Price Target Raised To $168 From $83 At Piper Jaffray

Image result for Sarepta Therapeutics

Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics to $168 from $83 after the company presented Phase I/II data on three Duchenne muscular dystrophy boys receiving its micro-dystrophin gene therapy. The stock closed yesterday up 37%, or $38.69, to $143.93.

The 38% micro-dystrophin expression increase exceeded expectations and is expected to translate into a functional benefit in up to 70% of boys, dramatically expanding the Exondys51 patient population, Tenthoff tells investors in a research note. He continues to project Exondys51 sales of $309M in 2018.

Further, a rolling new drug application submission on golodirsen by year-end 2018 could result in accelerated approval next year, the analyst adds. He maintains an Overweight rating on Sarepta after adding value for gene therapy. 

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.